---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-317784"
form_type: "8-K"
ticker: "ARTV"
cik: "0001817241"
company_name: "Artiva Biotherapeutics, Inc."
filed_at: "2025-12-12T23:59:59+00:00"
generated_at: "2026-05-16T13:22:49.949212+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Artiva Biotherapeutics exchanges underwater options for RSUs for CEO and COO

## Summary
- CEO Fred Aslan surrendered 869,136 options (566,470 vested, 302,666 unvested) for equivalent RSUs with new vesting.
- COO Jennifer Bush surrendered 84,877 options (60,372 vested, 24,506 unvested) for equivalent RSUs.
- RSUs vest between Aug 2026 and Feb 2029; acceleration on termination without cause or resignation for good reason.
- Purpose: retain employees and align interests with stockholders by replacing underwater options with current-value equity.

## SEC filing metadata
- accession: 0001193125-25-317784
- form_type: 8-K
- ticker: ARTV
- cik: 0001817241
- company_name: Artiva Biotherapeutics, Inc.
- filed_at: 2025-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817241/000119312525317784/0001193125-25-317784-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817241/000119312525317784/artv-20251210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-317784
- JSON: https://secwatch.observer/filing/0001193125-25-317784.json
- Plain text: https://secwatch.observer/filing/0001193125-25-317784.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.